Recruiting
Phase 2

Gemcitabine & Docetaxel

Sponsor:

University of Florida

Code:

NCT06488222

Conditions

Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Docetaxel

Gemcitabine

Study Details

Brief summary:

Bladder cancer is the 8th most common cancer in the UF Health Cancer Center catchment area and the 7th most common cancer presenting to UFHealth. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle invasion and no evidence of disease beyond the bladder. The current use in BCG (Bacillus Calmette-Guerin) refractory disease and the ongoing evaluation in BCG naïve high-risk disease support evaluation of intravesical gemcitabine and docetaxel in decreasing disease recurrence in intermediate risk stage I bladder cancer.

This study will investigate the efficacy and subject compliance with treatment of low grade intermediate risk bladder cancer with intravesical gemcitabine and docetaxel.

Conditions

Bladder Cancer

Study ID

NCT06488222

Start date

Nov 5, 2024

Status verified date

Mar, 2026

Completion date

Aug, 2027

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults ≥ 18 years of age.
  • Low-grade (Ta) Intermediate risk urothelial carcinoma of the bladder (defined as recurrent low-grade Ta, solitary low-grade Ta > 3 cm, multifocal low-grade Ta). Up to 10% high grade component is allowed.
  • ECOG Performance Status of 0-2.
  • No evidence of upper tract urothelial carcinoma based on CT, MRI, or retrograde pyelograms.
  • No urethral involvement based on cystoscopy.
  • No visible disease based on cystoscopy within 60 days of study enrollment.
  • Neutrophil counts ≥ 1500 cells/mm3
  • Platelet counts >100,000 cells/mm3
  • Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician or approved by the PI\] may be included.
  • Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 6 months after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, subjects of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
  • Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 3 months following the last dose of study drug.
  • Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.

Exclusion Criteria:

  • Subjects who have a history of high-grade urothelial carcinoma of the bladder or upper tracts
  • Prior treatment with intravesical BCG
  • Pure squamous cell carcinoma or adenocarcinoma
  • Any component of neuroendocrine carcinoma
  • Anatomic abnormalities that prohibit urethral catheter placement
  • Low bladder capacity (determined by the treating Urologist) which prohibits treatment with intravesical therapy.
  • Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 6 months after the last dose of study drug.
  • Subjects who are confirmed to be pregnant or breastfeeding.
  • History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
  • Administration of a vaccine containing live virus within 30 days prior to the first dose of trial treatment. Note: Most flu vaccines are killed viruses, with the exception of the intra-nasal vainer (Flu-Mist) which is an attenuated live virus and therefore prohibited for 30 days prior to first dose.
  • Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.

Study Design

Enrollment

34 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Docetaxel and Gemcitabine

All subjects will be treated with docetaxel and gemcitabine in 2 phases (induction and maintenance) following transurethral resection. Docetaxel and gemcitabine will be given weekly for six weeks during induction and will then be given every 30 days until up to 12 months after the start of induction therapy during maintenance.

Interventions

Docetaxel

Subjects will receive 40 mg docetaxel intravesically.

Gemcitabine

Subjects will receive 1 mg gemcitabine intravesically.

Primary outcome measure

  • Recurrence free survival [ Time Frame: 12 months after start of induction ]

Central Contacts and Locations

Central contacts

Karine Charles

352-294-5018kmcharles@ufl.edu

Locations

University of Florida

Recruiting

Gainesville, Florida, United States, 32608

Contacts

Karine Charles

352-294-5018kmcharles@ufl.edu

More Information

Sponsor

University of Florida

Last update posted

Mar 11, 2026

Last verified

Mar, 2026

Keywords

  • bladder cancer
  • transurethral resection
  • gemcitabine
  • docetaxel

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Florida on 2026-03-11.